Nadia Hindi Muniz

Tratamiento de pacientes con sarcomas de partes blandas, sarcomas óseos y GIST. Tratamiento sistémico, terapias dirigidas, ensayos clínicos.

Investigación:

• Investigador principal/Subinvestigador en más de 40 ensayos clínicos en sarcomas de partes blandas, óseos y GIST.
• Investigadora colaboradora en más de 20 proyectos de investigación traslacional.
• Investigadora principal en proyectos de investigación traslacional:

1. ESTUDIO DE REGISTRO DE TUMOR DE CÉLULAS GIGANTES EN ESPAÑA Y BÚSQUEDA DE FACTORES PRONÓSTICOS Y PREDICTIVOS DE RESPUESTA A DENOSUMAB. GEIS 26-ET9.
Entidad/es financiadora/s: GEIS - GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS
Fecha de inicio-fin: 30/03/2017 - 31/12/2020

2. GEIS 26 ET A8: lmmunomodulation factors in epithelioid sarcoma and alveolar soft part sarcoma.
Entidad/es financiadora/s: GEIS - GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS
Fecha de inicio-fin: 01/01/2017 - 31/12/2020

3. Estudio Exploratorio de Factores Pronósticos Moleculares Relacionados Con Genotipo en Gist
Entidad/es financiadora/s: CONSEJERÍA DE SALUD Y FAMILIAS
Cód. según financiadora: PC-0537-2016-0537
Fecha de inicio-fin: 20/12/2016 - 20/12/2019

4. Análisis exploratorio de factores moleculares de inmunomodulación y apoptosis en sarcomas
Entidad/es financiadora/s: GEIS (Proyecto jóvenes investigadores)
Fecha de inicio-fin: 2015 – 2017

Docencia:

• Colaboradora Docente de la Universidad Autónoma de Madrid y Universidad Alfonso X el Sabio
• Docente Master de Tumores Musculoesqueléticos de la Universidad Europea de Madrid
• Colaboradora Docente de la Universidad de Sevilla

Autora de más de 90 publicaciones en revistas indexadas, destacando:

1. J Martin-Broto; A Redondo; DS Moura; et al; N Hindi. 2022. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nat Commun. 13-1, pp.6278. https://doi.org/10.1038/s41467-022-33975-6.
2. J Martin-Broto; R Diaz-Betveritge; DS Moura; et al; N Hindi. 2025. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). J Clin Oncol. 43-3, pp.297-307.
3. E Palmerini; A Lopez-Pousa; G Grignani; A Redondo; N Hindi; et al. 2025. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. Cancer. 131-1, pp.e35628.
4. DS Moura; JM Lopez-Marti; I Benesova; et al; J Martin-Broto. 2024. Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial. Clin Can Res. 30-22, pp.5192-5206.
5. JL Mondaza-Hernandez; N Hindi; A Fernandez-Serra; et al. 2024. Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma. Ther Adv Med Oncol .16-17588359241293951.
6. DS Moura; D Lopez Lopez; D di Lernia; et al; J Martin-Broto. 2024. Shared germline genomic variants in two patients with double primary gastrointestinal stromal tumours (GISTs). J Med Genet .61-10, pp.927-934.
7. J Carrillo-Garcia; N Hindi; Magda Conceicao; et al. 2024. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor. Eur J Cancer .209, pp.114270.
8. J Martin Broto; N Hindi; DS Moura. 2024. Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions. Curr Opin Oncol .36-4, pp.269-275.
9. DS Moura; JL Móndaza-Hernandez; P Sanchez-Bustos; et al; J Martin-Broto. 2024. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study. Cell Mol Life Sci. 81-1, pp.219.
10. J Carrillo-García; S Lacerenza; N Hindi; et al. 2024. Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients. Cytokine. 177-156542.
11. J Carrillo-García; S Lacerenza; N Hindi; et al. 2024. Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain. Ther Adv Med Oncol. 16-17588359231220611.
12. N Hindi; A Razak; E Rosenbaum; et al. 2023. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry. ESMO Open. 8-6, pp.102045.
13. J Martin-Broto, A Olarte-García, R Fernandéz-Rodríguez, and N Hindi. 2024. Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma. Therapeutic Advances in Medical Oncology. 16. https://doi.org/10.1177/17588359231225044
14. C Torrado; M Camaño; N Hindi; et al. 2023. Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature. Cancers (Basel). 15-21, pp.5187.

15. Martin Broto J; Martinez J; MouraSD; et al; (19/19) Hindi. 2023. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDJB2A. Signal transduction and targeted therapy. 8-1. https://doi.org/10.1038/s41392-023-01661-8

16. S Attia; V Villalobos; N Hindi; et al. 2023. Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers (Basel). 15-19, pp.4871.

17. JY Blay; M von Mehren; RL Jones; et al; M Nathenson. 2023. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies. ESMO Open. 8-5, pp.101618.

18. Martin Broto J; Valverde C; Hindi N; et al. 2023. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. https://doi.org/10.1186/s12943-023-01832-9.

19. Nadia Hindi; Nadia Laack; Kevin Hong; Peter Hohenberger. 2023. Local Therapies for Metastatic Sarcoma: Why, When, and How?. Am Soc Clin Oncol Educ Book. 43, pp.e390554..

20. Roberta Sanfilippo; Nadia Hindi; Josefina Cruz Jurado; et al. 2023. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA Oncology. 9-5, pp.656-663.

21. N Hindi; J Carrillo-Garcia; E Blanco-Alcaina; et al; J Martin-Broto. 2023. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. Int J Mol Sci. 24-1, pp.856. https://doi.org/10.3390/ijms24010856

22. M Lopez-Alvarez; C Gonzalez-Aguilera; DS Moura; et al; J Martin-Broto. 2022. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas. Int J Mol Sci. 24-1, pp.680. https://doi.org/10.3390/ijms24010680.

23. N Hindi; R Haas. 2022. Management of Synovial Sarcoma and Myxoid Liposarcoma. Surg Oncol Clin N Am. 31-3, pp.547-558. https://doi.org/10.1016/j.soc.2022.03.012

24. JY Blay; E Palmerini; J Bollard; et al; et al. 2022. SELNET clinical practice guidelines for bone sarcoma. Crit Rev Oncol Hematol. 174, pp.10368. https://doi.org/10.1016/j.critrevonc.2022.103685

25. JY Blay; N Hindi; J Bollard; et al. 2022. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev. 102, pp.102312.

26. PG Casali; JY Blay; N Abecassis; et al; et al. 2022. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 33-1, pp.20-33.

27. SJ Strauss; AM Frezza; N Abecassis; et al; et al. 2021. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 32-12, pp.1520-1536.

28. A Gronchi; A Miah; AP dei Tos; et al; et al. 2021. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. S0923-7534(21)02184.

29. J Martin-Broto; JL Mondaza-Hernandez; DS Moura; N Hindi. 2021. A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. Cancers (Basel). 13-12, pp.2913.

30. N Hindi; I Carrasco-Garcia; A Sanchez-Camacho; et al; J Martin-Broto. 2020. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center.Cancers (Basel). 12-12, pp.3740.

31. J Martin-Broto; N Hindi; G Grignani; et al; JA Lopez-Martin. 2020. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. Journal for Immunotherapy of Cancer. 8-2, pp.e001561.

32. Martin-Broto J; Hindi N; Aguiar S Jr; et al; Blay JY.2020. Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. The Oncologist.
33. Martin-Broto J; Cruz J; Penel N; et al; Stacchiotti S. 2020. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.The Lancet. Oncology. 21(3), pp.456-466. ISSN 1474-5488. https://doi.org/10.1016/S1470-2045(19)30826-5
34. Martin-Broto J; Hindi N; Lopez-Pousa A; et al; Moura DS. 2020. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA oncology. ISSN 2374-2445. https://doi.org/10.1001/jamaoncol.2019.6584
35. Stacchiotti S; Ferrari S; Redondo A; et al; Martin-Broto J. 2019. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.The Lancet. Oncology. 20(9), pp.1252-1262. ISSN 1470-2045. https://doi.org/10.1016/S1470-2045(19)30319-5
36. Fucà G; Hindi N; Ray-Coquard I; et al; Sanfilippo R. 2019. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.The oncologist. 24(7), pp.e536-e541. ISSN 1083-7159. https://doi.org/10.1634/theoncologist.2018-03384
37. Martin-Broto J; Hindi N; Cruz J; et al; Lopez-Pousa A. 2019. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).The oncologist. 24(6), pp.e338-e346. ISSN 1083-7159. https://doi.org/10.1634/theoncologist.2018-0121
38. Martin-Broto J; Moura DS; Hindi N. 2019. Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply.The Lancet. Oncology. 20(3), pp.e128. ISSN 1470-2045. https://doi.org/10.1016/S1470-2045(19)30080-4
39. Gronchi A; Hindi N; Cruz J; et al; Martin-Broto J. 2019. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.EClinicalMedicine. 9, pp.35-43. ISSN 2589-5370. https://doi.org/10.1016/j.eclinm.2019.03.007
40. J Martin-Broto; DS Moura; N Hindi. 2019. Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply. Lancet Oncology. 20-(3):e128..
41. Martin-Broto J; Stacchiotti S; Lopez-Pousa A; et al; Cruz J. 2019. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.The Lancet. Oncology. 20(1), pp.134-144. ISSN 1470-2045. https://doi.org/10.1016/S1470-2045(18)30676-4
42. Hindi N; Casali PG; Morosi C; et al; Stacchiotti S. 2015. Imatinib in advanced chordoma: A retrospective case series analysis.European journal of cancer (Oxford, England : 1990).

Más de 100 comunicaciones en congresos nacionales e internacionales.

Beca de Investigación clínica de la Sociedad Española de Oncología Médica (SEOM)- 2012.